The FDA approved Sanofi's Admelog, or insulin lispro injection, as a treatment for adults with type 1 and type 2 diabetes and children with type 1 diabetes. Admelog has been approved as the first follow-on biologic version of Humalog, Eli Lilly and Co.'s fast-acting insulin.
Sanofi's Admelog approved by FDA as follow-on biologic of Lilly's Humalog
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.